© 2022 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#Achillion Pharmaceuticals

High Cure Rates After 6 or 8 Weeks of Achillion’s Hep C Regimen

The Phase IIb trial investigated the safety and efficacy of the JNJ-4178 regimen, which includes odalasvir, AL-335 and Olysio.

EASL 2017 Roundup: Continued Progress in Fighting Liver Disease

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

Janssen/Achillion’s Triple-Drug Hep C Regimen Cures All Those With Genotype 1

The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.

More Perfect Cure Rates for Achillion’s Six-Week Hep C Treatment

Achillion has released new data showing excellent results from six weeks of treatment with company’s odalasvir and Gilead’s sofosbuvir.

Achillion’s Hep C Med ACH-3102 Approved for Fast Track Status

ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...

Achillion’s ACH-1625 on FDA Fast Track

The FDA has assigned the Fast Track designation to Achillion Pharmaceuticals, Inc.’s ACH-1625
Advertisement

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. Our Privacy Policy

Manage

Hep uses cookies to provide necessary website functionality, improve your experience, analyze our traffic and personalize ads. By remaining on our website, you indicate your consent to our Privacy Policy and our Cookie Usage.